Daiichi Sankyo, Kowa end Japan marketing alliance
This article was originally published in Scrip
Executive Summary
Kowa and Daiichi Sankyo's mutual decision to terminate a marketing alliance for two drugs in Japan suggests a desire by the latter major firm to focus its commercial firepower in the cardiovascular area on upcoming new products.